High-throughput techniques to analyze the AML genome in greater depth have revealed novel mutations with putative roles in leukemogenesis. The use of prognostic biomarkers has allowed for a more ...

Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to ...

The following is a summary of “Elucidating the immune landscape and potential prognostic model in acute myeloid leukemia with TP53 mutation,” published in the September 2024 issue of Hematology by Zhu ...

“Because 78% of the older patients given LIT is classified as adverse-risk by 2022 ELN, we investigated the impact of molecular abnormalities to improve the ability to risk stratify ND AML ...

Acute myeloid leukemia is one of the deadliest cancers. Leukemic stem cells responsible for the disease are highly resistant to treatment. A new editorial paper was published in Oncotarget's ...

In May 2024, Kura Oncology announced completion of enrollment in the Phase 2 portion of KOMET-001, a registration-directed trial of ziftomenib in patients with R/R NPM1-mutant AML. Enrollment of the ...

The menin pathway is considered a driver for multiple genetic alterations of the disease, of which NPM1 mutations are among the most common, representing approximately 30% of AML cases.

Physicians have warned that babies born to parents  who smoke heavily or more than 20 sticks of cigarettes per day are at ...